Compare · ITMR vs RMD
ITMR vs RMD
Side-by-side comparison of Itamar Medical Ltd. (ITMR) and ResMed Inc. (RMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ITMR and RMD operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- RMD is the larger of the two at $31.49B, about 62.6x ITMR ($503.1M).
- RMD has hit the wire 2 times in the past 4 weeks while ITMR has been quiet.
- RMD has more recent analyst coverage (25 ratings vs 4 for ITMR).
- Company
- Itamar Medical Ltd.
- ResMed Inc.
- Price
- $30.87+0.85%
- $219.82+0.11%
- Market cap
- $503.1M
- $31.49B
- 1M return
- -
- -2.86%
- 1Y return
- -
- -6.09%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- n/a
- News (4w)
- 0
- 2
- Recent ratings
- 4
- 25
Itamar Medical Ltd.
Itamar Medical Ltd., a medical technology company, develops and commercializes non-invasive medical devices and solutions for the treatment of respiratory sleep disorders. The company offers medical devices based on Peripheral Arterial Tone (PAT) signal, which measures changes in the patient's peripheral arterial pulse volumes and various parameters of arterial activities. It provides WatchPAT device, which enable to conduct home sleep apnea tests for the treatment of sleep apnea, such as obstructive sleep apnea; EndoPAT device that diagnoses endothelial dysfunction; and Loop device, a wrist device for measuring and recording physiological parameters, such as SpO2, respiration rate, and heart rate. The company operates in the United States, Canada, Europe, Israel, Japan, rest of the Asia Pacific, and internationally. The company was formerly known as Itamar Medical (CM) 1997 Ltd. and changed its name to Itamar Medical Ltd. in July 2000. Itamar Medical Ltd. was incorporated in 1997 and is headquartered in Caesarea, Israel.
ResMed Inc.
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; AirView that enables remote monitoring, over-the-air trouble shooting, and changing of device settings; and myAir, a patient engagement application that offers sleep data and a daily score based on their previous night's data, as well as connectivity module and propeller solutions. In addition, it provides business management software and services to out-of-hospital providers, home medical equipment, pharmacy, home infusion, orthotics, and prosthetics; and HEALTHCAREfirst and MatrixCare solutions. The company markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Latest ITMR
- SEC Form 15-12B filed by Itamar Medical Ltd.
- SEC Form EFFECT filed by Itamar Medical Ltd.
- SEC Form EFFECT filed by Itamar Medical Ltd.
- SEC Form POS AM filed by Itamar Medical Ltd.
- SEC Form POS AM filed by Itamar Medical Ltd.
- SEC Form S-8 POS filed by Itamar Medical Ltd.
- SEC Form S-8 POS filed by Itamar Medical Ltd.
- SEC Form 25-NSE filed by Itamar Medical Ltd.
- SEC Form 6-K filed by Itamar Medical Ltd.
- SEC Form 6-K filed by Itamar Medical Ltd.
Latest RMD
- Analyst initiated coverage on ResMed
- SEC Form 4 filed by Farrell Michael J.
- SEC Form 4 filed by Sandercock Brett
- SEC Form 4 filed by Farrell Peter C
- SEC Form 144 filed by ResMed Inc.
- Resmed to Report Third Quarter Fiscal 2026 Earnings on April 30, 2026
- Amendment: SEC Form SCHEDULE 13G/A filed by ResMed Inc.
- Chairman and CEO Farrell Michael J. exercised 4,991 units of ResMed Common Stock at a strike of $146.34 and sold $1,252,902 worth of ResMed Common Stock (4,991 units at $251.03) (SEC Form 4)
- Director Farrell Peter C sold $520,440 worth of ResMed Common Stock (2,000 units at $260.22), decreasing direct ownership by 3% to 62,773 units (SEC Form 4)
- SEC Form 144 filed by ResMed Inc.